Procit is an Erythropoiesis Stimulating Agents (ESAs). ESAs are used to treat the blood-disorder anemia in patients with kidney failure or who are undergoing chemotherapy. The Food and Drug Administration warn that this class of drugs increase death and accelerate tumor growth in patients with several types of cancer, including breast and cervical. Prior labeling added to the drugs in November warned of similar risks in other types of cancers. The warnings apply to drugmaker Amgen's Aranesp and Epogen, as well as Procit, sold by Johnson & Johnson. Labeling approved by FDA said risks occurred when doctors treated patients with elevated levels of the drugs, which stimulate red blood cell levels.
Do not change medications without first consulting your doctor.
Name (Stock Symbol)
Johnson & Johnson (JNJ)
Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide.
The information provided on ClassAdvocate.com is general in nature,
does not apply to any particular factual situation, and is not and
should not be taken as legal or other professional advice. We make no
commitment or warranty that the factual, legal or any other information
on ClassAdvocate.com, or on any linked website, is accurate, complete,
error-free, or current. As such, you should not rely on such information,
and should seek professional advice if and as you determine appropriate.
ClassAdvocate.com is not a lawyer referral service, and no attorney-client
or confidential relationship is or should be formed by use of the site.
The investigations listed on ClassAdvocate.com are attorney advertisements
and do not in any way constitute a referral or endorsement by ClassAdvocate.com
or any approved or authorized lawyer referral service.